Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC.
暂无分享，去创建一个
L. Zhang | Se-Hoon Lee | C. Zhou | Y. Cheng | C. Wang | P. N. Morcos | L. Bu | T. Reungwetwattana | Jiaxi He | S. Kim | T. Liu | You Lu | E. Mitry | Junhu Zhou | J. Yang | L. Yang | Y. Zhang | T. Xu | T. Liu